Pacira rises as DOMA pushes for CEO ouster, board shake-up and sale
11/03/2026 17:19
** Shares of drugmaker Pacira BioSciences PCRX.O rise 2% to $22.78 premarket ** Activist investor DOMA Perpetual says it has nominated three directors to PCRX board and is seeking the removal of CEO Frank Lee, citing years of poor financial performance ** Says Pacira’s stock has fallen 56% over 10 years, 68% over five years and 30% during Lee’s tenure ** Adds Pacira is too small to effectively market its non-opioid surgery pain drug Exparel and urges a formal sale process ** Criticizes PCRX board for approving high executive pay and moving headquarters to San Francisco ** Shares rose ~37% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Pacira Biosciences
See all newsBrief: Pacira Biosciences Inc - Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees
Brief: Pacira Biosciences Urges Stockholders To Vote "For" Election Of Pacira's Nominees On Blue Proxy Card
Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
Brief: Doma Perpetual Capital Management Calls For Removal Of Pacira CEO And Strategic Sale
Brief: Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees